Pages that link to "Q36108614"

The following pages link to Targeted therapy in multiple myeloma (Q36108614):

Displaying 13 items.

• Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target (Q26995561) (← links)
• Recent advances in antimultiple myeloma drug development (Q33416297) (← links)
• Maintenance and Consolidation Strategies in Non-Hodgkin’s Lymphoma: A Review of the Data (Q33685903) (← links)
• MicroRNA: important player in the pathobiology of multiple myeloma (Q33786861) (← links)
• Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival (Q34451498) (← links)
• Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients. (Q35201790) (← links)
• Angiogenic inhibitors: a new therapeutic strategy in oncology (Q36306264) (← links)
• Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma (Q36413501) (← links)
• Estrogen hydroxylation in osteoporosis (Q36716938) (← links)
• Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma (Q36803165) (← links)
• Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma (Q36938798) (← links)
• Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line (Q39856387) (← links)
• Simultaneous determination of erlotinib and metabolites in human urine using capillary electrophoresis (Q87217793) (← links)